Skip to main content

Table 2 Safety results

From: Actual versus ideal body weight dosing of sugammadex in morbidly obese patients offers faster reversal of rocuronium- or vecuronium-induced deep or moderate neuromuscular block: a randomized clinical trial

 

Sugammadex 2 mg/kg ABW N = 38

Sugammadex 2 mg/kg IBW N = 38

Sugammadex 4 mg/kg ABW N = 38

Sugammadex 4 mg/kg IBW N = 36

Neostigmine + Glycopyrrolate N = 38

n (%)

n (%)

n (%)

n (%)

n (%)

TREATMENT-EMERGENT EVENTS

 Sinus Bradycardia

2 (5.3)

1 (2.6)

2 (5.3)

2 (5.6)

1 (2.6)

 Sinus Tachycardia

4 (10.5)

3 (7.9)

5 (13.2)

1 (2.8)

3 (7.9)

 Other Arrhythmias

0

1 (2.6)

0

0

1 (2.6)

EVENTS OF CLINICAL INTEREST

 Adjudicated Hypersensitivity

0

0

0

1 (2.8)

0

 Adjudicated Anaphylaxis

0

0

0

0

0

 Clinically Relevant ↓ HR

0

0

0

0

0

 Clinically Relevant ↑ HR

0

0

0

0

1 (2.6)

 Clinically Relevant Arrhythmia

0

1 (2.6)

1 (2.6)

0

0

OTHER ADVERSE EVENTS

 Drug-related Adverse Event

0

2 (5.3)

0

2 (5.6)

6 (15.8)

 Serious Adverse Event

1 (2.6)

2 (5.3)

0

3 (8.3)

3 (7.9)

 Death

0

0

0

0

1 (2.6)